

# Michael Hardy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/814297/publications.pdf>

Version: 2024-02-01

22  
papers

256  
citations

1170033

9  
h-index

1113639

15  
g-index

23  
all docs

23  
docs citations

23  
times ranked

403  
citing authors

#	ARTICLE	IF	CITATIONS
1	Study of in vitro thrombin generation after neutralization of heparin. International Journal of Laboratory Hematology, 2022, 44, 168-176.	0.7	8
2	Effect of tissue factor pathway inhibitor on thrombin generation assay. International Journal of Laboratory Hematology, 2022, 44, .	0.7	0
3	Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement. Journal of Clinical Medicine, 2022, 11, 1338.	1.0	4
4	Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?. Frontiers in Cardiovascular Medicine, 2022, 9, 864899.	1.1	1
5	The edoxabanâ€M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12680.	1.0	1
6	Are the DOAC plasma level thresholds appropriate for clinical decisionâ€making? A reappraisal using thrombin generation testing. International Journal of Laboratory Hematology, 2021, 43, e48-e51.	0.7	11
7	Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thrombosis Research, 2021, 197, 20-23.	0.8	36
8	Influence of C-reactive protein on thrombin generation assay. Clinical Chemistry and Laboratory Medicine, 2021, 59, e301-e305.	1.4	1
9	Could Daily Monitoring of Fibrin Related Markers Help Suspect a Thrombotic Event in COVID-19 Patients? A Prospective Pilot Study. TH Open, 2021, 05, e152-e154.	0.7	9
10	Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 1740.	1.0	43
11	Comparison is not reason: Pitfalls in reporting thrombin generation results in anticoagulated patients. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12523.	1.0	0
12	Impact of centrifugation on thrombin generation in healthy subjects and in patients treated with direct oral anticoagulants. International Journal of Laboratory Hematology, 2021, 43, 1585-1592.	0.7	2
13	The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. American Journal of Medicine, 2021, 134, 1295-1299.	0.6	16
14	Les risques de chronicisation de la prise en charge de la douleur chronique: vÃ©cus et enjeux en centre multidisciplinaire. Douleurs, 2021, 22, 245-251.	0.0	0
15	Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data. Data in Brief, 2020, 33, 106519.	0.5	19
16	Effects of Time-Interval since Blood Draw and of Anticoagulation on Platelet Testing (Count, Indices) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Clinical Medicine, 2020, 9, 2515.	1.0	17
17	Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thrombosis Journal, 2020, 18, 17.	0.9	52
18	Studies on hemostasis in COVIDâ€19 deserve careful reporting of the laboratory methods, their significance, and their limitations. Journal of Thrombosis and Haemostasis, 2020, 18, 3121-3124.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Severe cerebrospinal fluid-cutaneous fistula treated by an epidural tetrastarch patch. <i>European Journal of Anaesthesiology</i> , 2020, 37, 334-337.	0.7	1
20	Reduction of Preoperative Waiting Time Before Urgent Surgery for Patients on P2Y12 Inhibitors Using Multiple Electrode Aggregometry: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 424.	1.0	4
21	Assessment of low plasma concentrations of apixaban in the periprocedural setting. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 394-402.	0.7	5
22	Andexanet alfa for the reversal of factor Xa inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 387-397.	1.4	10